Role of androgens in the treatment of patients with low ovarian response
The objective of the current report was to provide a summary of knowledge concerning the treatment of women with poor ovarian response with androgens and androgen modulating agents. This involved a review of the literature. The literature search was performed using PubMed. Information concerning the role of androgens and androgen modulating agents in treating women with poor ovarian response is limited. The search of the literature yielded five studies and one case report concerning the treatment of poor responders with androgens. The variations in patient selection, type of androgens employed and the different duration of exposure preclude drawing any definite conclusions. Aromatase inhibitors block the conversion of androgens to oestrogens, thereby promoting an androgen-rich intrafollicular environment. The evidence presented in this review suggests a potential beneficial role for the use of aromatase inhibitors in treating women who have previously experienced failure of standard IVF protocols. The optimal dose and duration of this treatment is yet to be determined. Although the results of studies concerning LH supplementation in poor responders are conflicting, the latest Cochrane review on the use of recombinant LH for ovarian stimulation supports its use in poor responders, based on pooled pregnancy estimates.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2009 |
|---|---|
| Erschienen: |
2009 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Reproductive biomedicine online - 19(2009), 6 vom: 24. Dez., Seite 888-98 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Feigenberg, Tomer [VerfasserIn] |
|---|
| Themen: |
9002-67-9 |
|---|
| Anmerkungen: |
Date Completed 25.02.2010 Date Revised 17.09.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM193950154 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM193950154 | ||
| 003 | DE-627 | ||
| 005 | 20231223195730.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2009 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0647.xml |
| 035 | |a (DE-627)NLM193950154 | ||
| 035 | |a (NLM)20031033 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Feigenberg, Tomer |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Role of androgens in the treatment of patients with low ovarian response |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.02.2010 | ||
| 500 | |a Date Revised 17.09.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The objective of the current report was to provide a summary of knowledge concerning the treatment of women with poor ovarian response with androgens and androgen modulating agents. This involved a review of the literature. The literature search was performed using PubMed. Information concerning the role of androgens and androgen modulating agents in treating women with poor ovarian response is limited. The search of the literature yielded five studies and one case report concerning the treatment of poor responders with androgens. The variations in patient selection, type of androgens employed and the different duration of exposure preclude drawing any definite conclusions. Aromatase inhibitors block the conversion of androgens to oestrogens, thereby promoting an androgen-rich intrafollicular environment. The evidence presented in this review suggests a potential beneficial role for the use of aromatase inhibitors in treating women who have previously experienced failure of standard IVF protocols. The optimal dose and duration of this treatment is yet to be determined. Although the results of studies concerning LH supplementation in poor responders are conflicting, the latest Cochrane review on the use of recombinant LH for ovarian stimulation supports its use in poor responders, based on pooled pregnancy estimates | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Androgens |2 NLM | |
| 650 | 7 | |a Aromatase Inhibitors |2 NLM | |
| 650 | 7 | |a Fertility Agents, Female |2 NLM | |
| 650 | 7 | |a Luteinizing Hormone |2 NLM | |
| 650 | 7 | |a 9002-67-9 |2 NLM | |
| 700 | 1 | |a Simon, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Ben-Meir, Assaf |e verfasserin |4 aut | |
| 700 | 1 | |a Gielchinsky, Yuval |e verfasserin |4 aut | |
| 700 | 1 | |a Laufer, Neri |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Reproductive biomedicine online |d 2000 |g 19(2009), 6 vom: 24. Dez., Seite 888-98 |w (DE-627)NLM122062868 |x 1472-6491 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2009 |g number:6 |g day:24 |g month:12 |g pages:888-98 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2009 |e 6 |b 24 |c 12 |h 888-98 | ||